118. The pharmaceutical composition of claim 117, wherein the oral dosage form is a tablet or capsule.

119. The pharmaceutical composition of any one of claims 114 to 118, further comprising a second therapeutic agent.

120. Use of a compound of any one of claims 1 to 113 or the pharmaceutical composition of any one of claims 114 to 118 in the manufacture of a medicament for ~~A method for~~ the treatment, prevention, or amelioration of one or more symptoms of a PI3K-mediated disorder, disease, or condition in a subject~~, which comprises administering to the subject the compound of any one of claims 1 to 113 or the pharmaceutical composition of any one of claims 114 to 118~~.

121. The ~~method~~ use of claim 120, wherein the PI3K-mediated disorder, disease, or condition is an inflammatory disease.

122. The ~~method~~ use of claim 120 or 121, wherein the compound or the composition is to be administered in combination with a second therapeutic agent.

123. An *in vitro* method for modulating PI3K enzymatic activity, comprising contacting a PI3K enzyme with the compound of any one of claims 1 to 113 or the pharmaceutical composition of any one of claims 114 to 118.

124. The method of any one of claims 120 to 123, wherein the PI3K is a wild type.

125. The method of any one of claims 120 to 123, wherein the PI3K is a PI3K variant.

126. The method of any one of claims 120 to 125, wherein the PI3K is a Class I PI3K.

127. The method of claim 126, wherein the PI3K is p110γ.